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Identity 
Note: A classification of chronic (mature) B-cell 
lymphoproliferative disorders based on reproducible 
morphologic and immunologic criteria was proposed 
by the FAB group in 1989. Ever since a number of 
cytogenetic studies disclosed a remarkable degree of 
heterogeneity within each disease category. Herein, the 
main cytogenetic entities of chronic lymphocytic 
leukemia and related disorders, B-cell prolymphocytic 
leukemia, splenic lymphoma with villous lymphocytes 
are presented. 
Other disease subsets of B-cell CLD include the 
leukemic phase of follicle centre cell lymphoma, 
mantle cell lymphoma and lymphoplasmacytic 
lymphoma. The cytogenetic features of these forms of 
leukemic lymphoma are the described in the B-NHL 
classification. 
Comment: The incidence for each of these 
chromosome lesions (below) is higher when 
investigated by the more sensitive fluorescence in situ 
hybridization (FISH) technique: FISH detected 13q14 
deletions in 40-50% of the cases, +12 in 15-20% of the 
cases; 11q22-23 deletions in 7-10% of the cases; 17p13 
deletions in 15-20% of the cases. The prognostic 
significance for each of these anomalies, 11q- 
excluded, mainly derives from studies that used 
conventional cytogenetics and needs to be reassessed in 
the light of the more recent data provided by FISH 
analysis. 
Legend for immunophenotypes (below): +: positive in 
>90% of the cases; +/-: positive in more than 50% of 
the cases; -/+: positive in less than 50% of cases; -: 
positive in <10% of the cases; pan-B markers include 
CD19; CD20; CD79a R = rearranged; sIg: surface  
immunoglobulins; cyIg: cytoplasmic Ig; IgV genes: 
genes encoding for the variable portion of the Ig. MTC 
and mTC1: major translocation cluster and minor 
translocation cluster 1 of BCL1 region, respectively. 
Clinics and pathology 
Disease 
Chronic lymphocytic leukemia CD5+ B cell that has 
encountered the antigen and harbours hypermutated 
IgV genes. 
Phenotype/cell stem origin 
CD5+; CD23+; CD38+/-; CD22 weak+; FMC7-; sIg+ 
weak. 
Cytogenetics 
del(13q) (10-15% of the cases): Typical morphology; 
indolent disease; favourable prognosis if present as the 
sole change (Note: typical morphology (FAB criteria): 
more than 90% of neoplastic cells are represented by 
small lymphocytes (diameter less than 14 m, i.e. < two 
red blood cells); atypical morphology: 10-55% of the 
lymphocytes are larger than 14 m with few 
prolymphocytes (CLL mixed-cell type); the cases are 
usually referred to as CLL/PL if prolymphocytes 
predominate among large lymphoid cells; PLL: more 
than 55%, and usually >70% of the cells are 
prolymphocytes.). 
Disease 
Chronic lymphocytic leukemia CD5+ virgin 
recirculating B-cell with germline IgV genes. 
Phenotype/cell stem origin 
CD5+; CD23+; CD38-/+; CD22 weak+; FMC7-; sIg+ 
weak. 










+12 (10-15% of the cases): Frequent atypical 
morphology; relatively indolent disease; unfavourable 
prognosis as compared with other single chromosome 
aberrations, but not against complex karyotypes, 11q- 
or 17p-. 
Disease 
Chronic lymphocytic leukemia CD5+ recirculating B-
cell. 
Phenotype/cell stem origin 
CD5+; CD23+; CD22 weak+; FMC7-; sIg+ weak. 
Cytogenetics 
11q22-23 deletion (ATM gene involved) (5-6% of the 
cases): Usually typical morphology with karyotype 
instability; Relatively aggressive disease, with 
development of multiple adenopathies; Unfavourable 
prognosis. 
del(17p) (p53 gene involved) (<5% of the cases): 
Morphology consistent with CLL/PL Advanced 
disease; Refractoriness to purine analougs; 
Unfavourable prognosis. 
t(11;14)(q13;q32) (BCL1 involved, mainly in the MTC 
and mTC1)(<5% of the cases): Rare cases of CLL/PL, 
transforming into prolymphocytic leukemia; Primary 
blood and marrow involvement, usually with 
splenomegaly, without adenopathy. 
Disease 
Prolymphocytic leukemia (PLL). 
Phenotype/cell stem origin 
Peripheral B-lymphocyte that has encountered the 
antigen and harbours hypermutated IgV genes. 
Clinics 
Rare and aggressive disease with a majority of 
relatively large lymphocytes with round nucleus and a 
prominent central nucleolus. 
Cytogenetics 
t(11;14)(q13;q32) (BCL1 involved in the MTC and 
mTC1). 
Disease 
Splenic lymphoma with villous lymphocytes. 
Phenotype/cell stem origin 
Marginal zone lymphocytes harbouring hypermutated 
IgV genes. 
Pan-B+; CD5-/+; CD23-/+; CD11c+/-; CD25-/+; 
FMC7+/-; sIg+ bright. 
Clinics 
Indolent disease; There are not established correlations 
between chromosome lesions and hematologic features; 
Cases with t(11;14) showed frequent CD5-positivity 
and featured an indolent course. 
Cytogenetics 
(20% of the cases) (breaks outside the MTC and mTC1 
of BCL1). 
(20-40% of cases) with or without +3. 
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